Impella in Cardiogenic Shock: Who and When?
Highlights
- • Optimal timing and selection of patients is the key for success.
- • Haemodynamic parameters improved within 24 h of Impella implantation.
- • Reductions in inotropic support and improvement in renal function, liver function and tissue perfusion.
- • INTERMARCS and SCAI classifications are, indeed, dynamic, but not subjective.
- • We are awaiting the results of the The DanGer Shock trial recruiting patient in an early shock phase.